Xinmin Zhao

928 total citations
47 papers, 666 citations indexed

About

Xinmin Zhao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Xinmin Zhao has authored 47 papers receiving a total of 666 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 17 papers in Cancer Research. Recurrent topics in Xinmin Zhao's work include Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (10 papers) and Cancer Treatment and Pharmacology (7 papers). Xinmin Zhao is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (10 papers) and Cancer Treatment and Pharmacology (7 papers). Xinmin Zhao collaborates with scholars based in China, United States and Japan. Xinmin Zhao's co-authors include Haiyi Guo, Fangfang Lv, Chunlei Zheng, Xianghua Wu, Xichun Hu, Li Jin, Jun Qian, Lei Chen, Feng‐Qing Wang and Chuan Li and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Xinmin Zhao

45 papers receiving 656 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xinmin Zhao China 13 354 263 259 138 78 47 666
Soo Hee Kim South Korea 13 330 0.9× 207 0.8× 286 1.1× 158 1.1× 94 1.2× 37 652
Anne‐Claire Voegeli France 15 355 1.0× 305 1.2× 462 1.8× 155 1.1× 79 1.0× 25 772
Fangchao Zheng China 9 425 1.2× 272 1.0× 278 1.1× 203 1.5× 51 0.7× 33 800
Kyungsoo Jung South Korea 13 299 0.8× 224 0.9× 400 1.5× 196 1.4× 59 0.8× 20 663
Kara Penne United States 7 256 0.7× 260 1.0× 203 0.8× 154 1.1× 88 1.1× 11 691
Shotaro Iwakiri Japan 11 399 1.1× 237 0.9× 370 1.4× 107 0.8× 52 0.7× 17 682
F. De Vita Italy 11 405 1.1× 198 0.8× 196 0.8× 220 1.6× 67 0.9× 37 691
Daniel Brungs Australia 14 322 0.9× 180 0.7× 151 0.6× 175 1.3× 51 0.7× 47 565
Karen A. Cadoo United States 19 365 1.0× 241 0.9× 211 0.8× 162 1.2× 106 1.4× 74 868
Giulia Orsi Italy 12 220 0.6× 171 0.7× 148 0.6× 113 0.8× 55 0.7× 34 514

Countries citing papers authored by Xinmin Zhao

Since Specialization
Citations

This map shows the geographic impact of Xinmin Zhao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinmin Zhao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinmin Zhao more than expected).

Fields of papers citing papers by Xinmin Zhao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xinmin Zhao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinmin Zhao. The network helps show where Xinmin Zhao may publish in the future.

Co-authorship network of co-authors of Xinmin Zhao

This figure shows the co-authorship network connecting the top 25 collaborators of Xinmin Zhao. A scholar is included among the top collaborators of Xinmin Zhao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xinmin Zhao. Xinmin Zhao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Xin, Wenyue Yang, Zhen Wang, et al.. (2024). Plasma extracellular vesicle long RNA profiling identifies a predictive signature for immunochemotherapy efficacy in lung squamous cell carcinoma. Frontiers in Immunology. 15. 1421604–1421604. 1 indexed citations
2.
Lin, Ying, Bo Yu, Hongyu Zhang, et al.. (2023). Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor. Journal of Cancer Research and Clinical Oncology. 149(11). 8663–8671. 20 indexed citations
3.
Lai, Hongyan, Chang Liu, Xin Zhang, et al.. (2023). Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer. Cancer Science. 114(7). 2774–2786. 6 indexed citations
4.
Wang, Wei, et al.. (2023). Transanal drainage tube for the prevention of anastomotic leakage in anterior resection for rectal cancer: a systematic review and meta-analysis. Expert Review of Anticancer Therapy. 23(4). 431–442. 3 indexed citations
5.
Zhao, Xinmin, Xianghua Wu, Hui Yu, et al.. (2022). Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors. Frontiers in Immunology. 13. 1003581–1003581. 4 indexed citations
6.
7.
Wang, Weiping, et al.. (2019). Effect of Ultrasound Debridement on Serum Inflammatory Factors and bFGF, EGF Expression in Wound Tissues. Journal of College of Physicians And Surgeons Pakistan. 29(3). 222–225. 4 indexed citations
8.
9.
Zhao, Xinmin, et al.. (2016). PA-MSHA inhibits proliferation and induces apoptosis in human non-small cell lung cancer cell lines with different genotypes. Molecular Medicine Reports. 14(6). 5369–5376. 8 indexed citations
10.
11.
Zhao, Xinmin & Xichun Hu. (2015). Dosing of zoledronic acid with its anti-tumor effects in breast cancer. Journal of bone oncology. 4(3). 98–101. 21 indexed citations
12.
Zhou, Xiaoyan, Xinmin Zhao, Si Sun, et al.. (2014). A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib. Medical Oncology. 31(7). 36–36. 5 indexed citations
13.
Lv, Fangfang, Jun Cao, Jian Zhang, et al.. (2014). Phase II study of pseudomonas aeruginosa-mannose-sensitive hemagglutinin in combination with capecitabine for HER2-negative metastatic breast cancer pretreated with anthracycline and taxane.. Journal of Clinical Oncology. 32(15_suppl). 1053–1053. 1 indexed citations
14.
Lu, Renquan, Zhujun Chen, Xiaofeng Xu, et al.. (2013). Lactate Dehydrogenase 5 Expression in Non-Hodgkin Lymphoma Is Associated with the Induced Hypoxia Regulated Protein and Poor Prognosis. PLoS ONE. 8(9). e74853–e74853. 32 indexed citations
15.
Zhao, Xinmin, Xiaofeng Xu, Qunling Zhang, et al.. (2011). Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid. BMC Cancer. 11(1). 403–403. 16 indexed citations
16.
Jin, Li, Xinmin Zhao, Lei Chen, et al.. (2010). Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 10(1). 529–529. 219 indexed citations
17.
Qiu, Li‐Xin, Xiaodong Zhu, Chunlei Zheng, et al.. (2010). The p21 Ser31Arg polymorphism and breast cancer risk: a meta-analysis involving 51,236 subjects. Breast Cancer Research and Treatment. 124(2). 475–479. 16 indexed citations
18.
Qiu, Li‐Xin, Lei Yao, Jian Zhang, et al.. (2010). XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects. Breast Cancer Research and Treatment. 124(1). 229–235. 23 indexed citations
19.
Zhao, Xinmin, Xiaofeng Xu, Lin Guo, et al.. (2010). Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance. Breast Cancer Research and Treatment. 124(3). 733–743. 27 indexed citations
20.
Zhao, Xinmin, Zhonghua Wang, Xiaonan Hong, et al.. (2008). Biweekly docetaxel-containing chemotherapy may be the optimal schedule. Anti-Cancer Drugs. 19(4). 421–426.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Soo Hee Kim Breakdown of academic impact, for papers by Anne‐Claire Voegeli Breakdown of academic impact, for papers by Fangchao Zheng Breakdown of academic impact, for papers by Kyungsoo Jung Breakdown of academic impact, for papers by Kara Penne Breakdown of academic impact, for papers by Shotaro Iwakiri Breakdown of academic impact, for papers by F. De Vita Breakdown of academic impact, for papers by Daniel Brungs Breakdown of academic impact, for papers by Karen A. Cadoo Breakdown of academic impact, for papers by Giulia Orsi
Rankless by CCL
2026